Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

With reports on the formation of blood clots in some recipients of the AstraZeneca&nbsp;Covid&nbsp;vaccine, many in India are hesitant to take the vaccine. On today's episode of Ask The Doctor, Dr Tapish&nbsp;Sahu,&nbsp;Consultant, Peripheral Vascular &amp; Endovascular Sciences Division, Medanta Hospital, explains why its a bad idea to take blood thinners without medical supervision. He says vaccines are life-saving and the benefits&nbsp;outweigh the risk, moreover blood clots are treatable if detected in time.

Ask The Doctor | Don't self-medicate yourself with blood thinners, say doctors

Ask The Doctor | Don't self-medicate with blood thinners, say doctors

With reports on the formation of blood clots in some recipients of the AstraZeneca&nbsp;Covid&nbsp;vaccine, many in India are hesitant to take the vaccine. On today's episode of Ask The Doctor, Dr Tapish&nbsp;Sahu,&nbsp;Consultant, Peripheral Vascular &amp; Endovascular Sciences Division, Medanta Hospital, explains why its a bad idea to take blood thinners without medical supervision. He says vaccines are life-saving and the benefits&nbsp;outweigh the risk, moreover blood clots are treatable if detected in time.

As several countries grapple with new, dangerous Covid strains, Oxford scientists are preparing to rapidly produce new versions of their vaccine to combat the new virus variant, The Telegraph reported on Wednesday. New, more infectious variants of Covid-19 have emerged in the UK, South Africa and Brazil, and have spread to many parts of the world. The team behind the vaccine from Oxford and AstraZeneca is undertaking feasibility studies to reconfigure the technology, the newspaper said. British Prime Minister Boris Johnson said on Wednesday that the nation's medicines regulator will be ready and able to give approval to new versions of Covid-19 vaccines designed to counter new variants of the coronavirus that may appear.

Oxford team preparing Covid vaccine variants to fight new strains

Oxford scientists are preparing to rapidly produce new versions of their Covid-19&nbsp;vaccine to combat the new virus variant, says report

As several countries grapple with new, dangerous Covid strains, Oxford scientists are preparing to rapidly produce new versions of their vaccine to combat the new virus variant, The Telegraph reported on Wednesday. New, more infectious variants of Covid-19 have emerged in the UK, South Africa and Brazil, and have spread to many parts of the world. The team behind the vaccine from Oxford and AstraZeneca is undertaking feasibility studies to reconfigure the technology, the newspaper said.

As several countries grapple with new, dangerous Covid strains, Oxford scientists are preparing to rapidly produce new versions of their vaccine to combat the new virus variant, The Telegraph reported on Wednesday. New, more infectious variants of Covid-19 have emerged in the UK, South Africa and Brazil, and have spread to many parts of the world. The team behind the vaccine from Oxford and AstraZeneca is undertaking feasibility studies to reconfigure the technology, the newspaper said. British Prime Minister Boris Johnson said on Wednesday that the nation's medicines regulator will be ready and able to give approval to new versions of Covid-19 vaccines designed to counter new variants of the coronavirus that may appear.

The UK is set to roll out the Oxford-AstraZeneca coronavirus jab on Monday, days after approving the vaccine. More than half a million doses of the vaccine are ready for use as the UK accelerates its vaccine programme to tackle a surge in cases. The govt described it as a "pivotal moment" in the UK's fight against the virus, as vaccines will help curb infections and, ultimately, allow restrictions to be lifted. On Sunday more than 50,000 new confirmed Covid cases were recorded in the UK for the sixth day running. PM Boris Johnson has warned tougher virus rules may be needed in the short-term.

UK rolls out Oxford vaccine, 1st jab given to 82-year-old patient

The UK is set to roll out the Oxford-AstraZeneca coronavirus jab on Monday, days after approving the vaccine. PM warns of tougher curbs to contain Covid-91 cases

Covid cases surge, UK set to roll out Oxford vaccine

UK rolled out the Oxford-AstraZeneca coronavirus jab on Monday, days after approving the vaccine.&nbsp;
The "game-changing" coronavirus vaccine from Oxford University and AstraZeneca was given to its first patient in the UK.
The jab, which is cheaper and easier to roll out en masse than the Pfizer vaccine, was administered to 82-year-old Brian Pinker at Oxford University Hospital
More than half a million doses of the vaccine are ready for use as the UK accelerates its vaccine programme to tackle a surge in cases. The govt described it as a "pivotal moment" in the UK's fight against the virus, as vaccines will help curb infections and, ultimately, allow restrictions to be lifted.&nbsp;

UK rolled out the Oxford-AstraZeneca coronavirus jab on Monday, days after approving the vaccine.&nbsp;
The "game-changing" coronavirus vaccine from Oxford University and AstraZeneca was given to its first patient in the UK. The jab, which is cheaper and easier to roll out en masse than the Pfizer vaccine, was administered to 82-year-old Brian Pinker at Oxford University Hospital
More than half a million doses of the vaccine are ready for use as the UK accelerates its vaccine programme to tackle a surge in cases. The govt described it as a "pivotal moment" in the UK's fight against the virus, as vaccines will help curb infections and, ultimately, allow restrictions to be lifted.&nbsp;

UK govt clearing the Oxford vaccine against coronavirus is great news for India. An expert panel on Covid vaccine is likely to meet in a few days to decide on granting emergency use approval to the Oxford vaccine in India. So why is this vaccine best bet for India:The vaccine has proved to be 90% effective in trialsIt is being manufactured by Pune based Serum Institute, which so availability is assured.The vaccine will be cheaper than Pfizer and Moderna vaccineSerum CEO Adar Poonawalla has said that the drugmaker will sell it to govt at ₹250 per vial of two doses. In market, it's likely to cost ₹1000 per vial.And most importantly, the Oxford vaccine can be stored at 2 to 8 degree whereas the Pfizer vaccine needs to be stored at -70 degrees, which will be impossible in India.So India can now expect to start vaccinations soon after the govt nod as Serum has said that most of the 50 million first doses will be available for India.

UK nod to Oxford vaccine good news for India. Here's why

UK govt clearing the Oxford vaccine against coronavirus is great news for India. Here's why

UK govt clearing the Oxford vaccine against coronavirus is great news for India. An expert panel on Covid vaccine is likely to meet in a few days to decide on granting emergency use approval to the Oxford vaccine in India. So why is this vaccine best bet for India: The vaccine has proved to be 90% effective in trials It is being manufactured by Pune based Serum Institute, which so availability is assured. The vaccine will be cheaper than Pfizer and Moderna vaccine Serum CEO Adar Poonawalla has said that the drugmaker will sell it to govt at ₹250 per vial of two doses. In market, it's likely to cost ₹1000 per vial. And most importantly, the Oxford vaccine can be stored at 2 to 8 degree whereas the Pfizer vaccine needs to be stored at -70 degrees, which will be impossible in India. So India can now expect to start vaccinations soon after the govt nod as Serum has said that most of the 50 million first doses will be available for India.

Serum Institute of India CEO Adar Poonawalla on Monday said that majority of the first 50 million doses of the Covid vaccine that the company is producing will go to India. Serum is testing and manufacturing&nbsp;the Oxford vaccine against coronavirus and hopes to get govt approval for emergency use in a few days. Poonawalla has said that at least for the first month, most of the doses will go to India. He added that though the drugmaker has a deal with other COVAX countries, but for exporting it will need approvals from World Health Organisation and licenses. "So, India will receive first," Poonawalla said. He added that the vaccine shortage would ease by middle of 2021 "because there will be so many manufacturers by then".

India will get most of first 50mn Oxford shots: Serum CEO

Serum Institute of India CEO Adar Poonawalla on Monday said that majority of the first 50 million doses of the Covid vaccine that the company is producing will go to India

Serum Institute of India CEO Adar Poonawalla on Monday said that majority of the first 50 million doses of the Covid vaccine that the company is producing will go to India. Serum is testing and manufacturing&nbsp;the Oxford vaccine against coronavirus and hopes to get govt approval for emergency use in a few days. Poonawalla has said that at least for the first month, most of the doses will go to India. He added that though the drugmaker has a deal with other COVAX countries, but for exporting it will need approvals from World Health Organisation and licenses. "So, India will receive first," Poonawalla said.

Serum Institute of India CEO Adar Poonawalla on Monday said that majority of the first 50 million doses of the Covid vaccine that the company is producing will go to India. Serum is testing and manufacturing&nbsp;the Oxford vaccine against coronavirus and hopes to get govt approval for emergency use in a few days. Poonawalla has said that at least for the first month, most of the doses will go to India. He added that though the drugmaker has a deal with other COVAX countries, but for exporting it will need approvals from World Health Organisation and licenses. "So, India will receive first," Poonawalla said. He added that the vaccine shortage would ease by middle of 2021 "because there will be so many manufacturers by then".

While India has started preparing for a Covid vaccine rollout, New Delhi is reportedly waiting for the UK govt nod to Oxford vaccine. News agency PTI has reported that Britain is likely to clear the Oxford-AstraZeneca shot in the coming week. Once the UK drug regulator gives its approval, the expert committee on Covid-19 at the Central Drugs Standard Control Organisation will study the vaccine trials data to decide on emergency use approval. The process of granting emergency use approval for Bharat Biotech's 'Covaxin" may take time as its phase 3 trials are still underway, while Pfizer is yet to make a presentation. "Going by this, Oxford vaccine 'Covishield' is likely to be the first to be rolled out in India," report said quoting sources.

Oxford vaccine likely to be first to get India approval

While India has started preparing for a Covid vaccine rollout, New Delhi is reportedly waiting for the UK govt nod to Oxford vaccine

While India has started preparing for a Covid vaccine rollout, New Delhi is reportedly waiting for the UK govt nod to Oxford vaccine. News agency PTI has reported that Britain is likely to clear the Oxford-AstraZeneca shot in the coming week. The process of granting emergency use approval for Bharat Biotech's 'Covaxin" may take time as its phase 3 trials are still underway, while Pfizer is yet to make a presentation. "Going by this, Oxford vaccine 'Covishield' is likely to be the first to be rolled out in India," report said quoting sources.

While India has started preparing for a Covid vaccine rollout, New Delhi is reportedly waiting for the UK govt nod to Oxford vaccine. News agency PTI has reported that Britain is likely to clear the Oxford-AstraZeneca shot in the coming week. Once the UK drug regulator gives its approval, the expert committee on Covid-19 at the Central Drugs Standard Control Organisation will study the vaccine trials data to decide on emergency use approval. The process of granting emergency use approval for Bharat Biotech's 'Covaxin" may take time as its phase 3 trials are still underway, while Pfizer is yet to make a presentation. "Going by this, Oxford vaccine 'Covishield' is likely to be the first to be rolled out in India," report said quoting sources.

The University of Oxford and drug maker AstraZeneca have applied to the UK health regulator for permission to roll out their Covid-19 vaccine, Health Minister Matt Hancock said on Wednesday. He added that the Oxford AstraZeneca vaccine developed in the UK has submitted its full data package to the regulator for approval. The Pfizer/BioNTech vaccine was the first coronavirus shot to be authorised for use by the UK's independent medicines regulator. It has been given to over 5 lakh of the country's most vulnerable people since its rollout last month.

Oxford-AstraZeneca Covid vaccine submitted for UK nod

The University of Oxford and drug maker AstraZeneca have applied to the UK health regulator for permission to roll out their Covid-19 vaccine

Oxford-AstraZeneca Covid vaccine submitted for UK approval

The University of Oxford and drug maker AstraZeneca have applied to the UK health regulator for permission to roll out their Covid-19 vaccine, Health Minister Matt Hancock said on Wednesday. He added that the Oxford AstraZeneca vaccine developed in the UK has submitted its full data package to the regulator for approval. The Pfizer/BioNTech vaccine was the first coronavirus shot to be authorised for use by the UK's independent medicines regulator. It has been given to over 5 lakh of the country's most vulnerable people since its rollout last month.

India is likely to approve Oxford coronavirus vaccine for emergency use by next week, news agency Reuters has reported quoting sources. Central Drugs Standard Control Organization reviewed Oxford-AstraZeneca application on December 9 and had sought more information from Serum Institute of India, which is making the AstraZeneca shots. According to the report, Serum has submitted additional data sought by authorities. If India gives go ahead, it could be the first country to clear the British drugmaker&rsquo;s vaccine as the British medicine regulator continues to examine data from the trials.
&nbsp;

India likely to approve Oxford vaccine by next week

India is likely to approve Oxford coronavirus vaccine for emergency use by next week, news agency Reuters has reported

India is likely to approve Oxford coronavirus vaccine for emergency use by next week, news agency Reuters has reported quoting sources. Central Drugs Standard Control Organization reviewed Oxford-AstraZeneca application on December 9 and had sought more information from Serum Institute of India, which is making the AstraZeneca shots. According to the report, Serum has submitted additional data sought by authorities. If India gives go ahead, it could be the first country to clear the British drugmaker&rsquo;s vaccine as the British medicine regulator continues to examine data from the trials.
&nbsp;

Oxford&rsquo;s Covid-19 vaccine has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster, the university said on Thursday. The details from the Phase I/II clinical trials released on Thursday made no reference to the half-dose/full-dose regime, which Oxford has said had been &ldquo;unplanned&rdquo; but approved by regulators, Reuters has reported. The vaccine &ldquo;stimulates broad antibody and T cell functions,&rdquo; it said after publishing further data from the Phase I/II clinical trials.

Oxford: Vaccine has good immune response with 2-dose regime

Oxford has said that its&nbsp;Covid-19 vaccine has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster

Oxford&rsquo;s Covid-19 vaccine has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster, the university said on Thursday. The details from the Phase I/II clinical trials released on Thursday made no reference to the half-dose/full-dose regime, which Oxford has said had been &ldquo;unplanned&rdquo; but approved by regulators, Reuters has reported. The vaccine &ldquo;stimulates broad antibody and T cell functions,&rdquo; it said after publishing further data from the Phase I/II clinical trials.

Serum Institute gets nod to resume Covid vaccine trials

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate. The DCGI, Dr V G Somani, has however, put certain conditions like taking extra care during screening, providing additional information in informed consent to be followed during the trials. The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a volunteer.

New Delhi, PTI: Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII).
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ''an unexplained illness'' in a participant in the study.
On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for Covid-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.
According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.
DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.
According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants.

oxford covid 19 vaccine

Categories